Letter by Kunz et al Regarding Article, “Systematic Review of the Cost and Cost-Effectiveness of Rapid Endovascular Therapy for Acute Ischemic Stroke”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the article by Sevick et al1 that systematically reviewed and synthesized the literature on cost-effectiveness of endovascular therapy combined with standard care (EVT+SC) in acute ischemic large-vessel occlusion stroke. The authors conclude that EVT+SC is a cost-effective intervention when adopting willingness-to-pay thresholds of $50 000 per quality-adjusted life year compared with SC alone. Sevick et al also demonstrate the applicability of this conclusion across several different healthcare systems in Europe and North America.
We would like to highlight and add an important recent aspect about the source of cost data in the United States to this review. In the recently published cost-effectiveness analysis by Shireman et al,2 the …